Impurities in Oligonucleotide Drug Substances and Drug Products

被引：78

作者：

Capaldi, Daniel ^{[1
]}

Teasdale, Andy ^{[2
]}

Henry, Scott ^{[1
]}

Akhtar, Nadim ^{[2
]}

den Besten, Cathaline ^{[3
]}

Gao-Sheridan, Samantha ^{[4
]}

Kretschmer, Matthias ^{[4
]}

Sharpe, Neal ^{[5
]}

Andrews, Ben ^{[6
]}

Burm, Brigitte ^{[7
]}

Foy, Jeffrey ^{[8
]}

机构：

[1] Ionis Pharmaceut Inc, 2855 Gazelle Court, Carlsbad, CA 92010 USA

[2] AstraZeneca UK Ltd, Macclesfield, Cheshire, England

[3] ProQR Therapeut NV, Leiden, Netherlands

[4] Alnylam Pharmaceut Inc, Cambridge, MA USA

[5] Anavex Life Sci Corp, New York, NY USA

[6] GlaxoSmithKline, Stevenage, Herts, England

[7] ISA Therapeut, Leiden, Netherlands

[8] Celgene Corp, Summit, NJ USA

来源：

NUCLEIC ACID THERAPEUTICS | 2017年 / 27卷 / 06期

关键词：

oligonucleotides; impurities; identification; qualification; PERFORMANCE LIQUID-CHROMATOGRAPHY; CAPILLARY GEL-ELECTROPHORESIS; IONIZATION MASS-SPECTROMETRY; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; INTERFERING RNA; NUCLEIC-ACIDS; THERAPEUTICS; DNA; RECOMMENDATIONS; OLIGODEOXYNUCLEOTIDES;

D O I：

10.1089/nat.2017.0691

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

This white paper, which is the 10th in a series intended to address issues associated with the development of therapeutic oligonucleotides, examines the subject of product-related impurities. The authors consider chemistry and safety aspects and advance arguments in favor of platform approaches to impurity identification and qualification. Reporting, identification, and qualification thresholds suitable for product-related impurities of therapeutic oligonucleotides are proposed.

引用

页码：309 / 322

页数：14

共 55 条

[1] Clinical Expert Panel on Monitoring Potential Lung Toxicity of Inhaled Oligonucleotides: Consensus Points and Recommendations
Alton, Eric W.
Boushey, Homer A.
Garn, Holger
Green, Francis H.
Hodges, Michael
Martin, Richard J.
Murdoch, Robert D.
Renz, Harald
Shrewsbury, Stephen B.
Seguin, Rosanne
Johnson, Graham
Parry, Joel D.
Tepper, Jeff
Renzi, Paolo
Cavagnaro, Joy
Ferrari, Nicolay
[J]. NUCLEIC ACID THERAPEUTICS, 2012, 22 (04) : 246 - 254
[2] Analysis of oligonucleotides by HPLC-electrospray ionization mass spectrometry
Apffel, A
Chakel, JA
Fischer, S
Lichtenwalter, K
Hancock, WS
[J]. ANALYTICAL CHEMISTRY, 1997, 69 (07) : 1320 - 1325
[3] SEPARATION OF SYNTHETIC PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES FROM THEIR OXYGENATED (PHOSPHODIESTER) DEFECT SPECIES BY STRONG-ANION-EXCHANGE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
BERGOT, BJ
EGAN, W
[J]. JOURNAL OF CHROMATOGRAPHY, 1992, 599 (1-2): : 35 - 42
[4] OSWG Recommendations for Genotoxicity Testing of Novel Oligonucleotide-Based Therapeutics
Berman, Cindy L.
Barros, Scott A.
Galloway, Sheila M.
Kasper, Peter
Oleson, Frederick B.
Priestley, Catherine C.
Sweder, Kevin S.
Schlosser, Michael J.
Sobol, Zhanna
[J]. NUCLEIC ACID THERAPEUTICS, 2016, 26 (02) : 73 - 85
[5] Recommendations for Safety Pharmacology Evaluations of Oligonucleotide-Based Therapeutics
Berman, Cindy L.
Cannon, Keri
Cui, Yi
Kornbrust, Douglas J.
Lagrutta, Armando
Sun, Sunny Z.
Tepper, Jeff
Waldron, Gareth
Younis, Husam S.
[J]. NUCLEIC ACID THERAPEUTICS, 2014, 24 (04) : 291 - 301
[6] Liquid chromatography electrospray ionization mass spectrometry analysis of the ocular metabolites from a short interfering RNA duplex
Beverly, M
Hartsough, K
Machemer, L
Pavco, P
Lockridge, J
[J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2006, 835 (1-2): : 62 - 70
[7] Bonilla JV., 2011, Handbook of Analysis of Oligonucleotides and Related Products
[8] LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY OF ANTISENSE OLIGONUCLEOTIDES
BOTHNER, B
CHATMAN, K
SARKISIAN, M
SIUZDAK, G
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (23) : 2863 - 2868
[9] Chemistry at the 2′ Position of Constituent Nucleotides Controls Degradation Pathways of Highly Modified Oligonucleotide Molecules
Calvitt, C. Jeffrey
Levin, Daren S.
Shepperd, Benjamin T.
Gruenloh, Christopher J.
[J]. OLIGONUCLEOTIDES, 2010, 20 (05) : 239 - 251
[10] Capaldi D. C., 2008, ANTISENSE DRUG TECHN, P401

← 1 2 3 4 5 6 →